|
|
DDO (Defective derived oligonucleotide) |
|
Vaxjo ID |
128 |
|
Vaccine Adjuvant Name |
DDO (Defective derived oligonucleotide) |
|
Adjuvant VO ID |
VO_0005294
|
|
Description |
Synthetic derivative of natural compound, nucleic acid with TLR3 receptor that induces Th1 response |
|
Stage of Development |
Research |
|
Location Licensed |
US (WASHU) |
|
Host Species for Testing |
Mouse |
|
Components |
268nt DVG-derived oligonucleotide (DDO) / SeV-derived oligonucleotides |
|
Function |
Type: nucleic acid vaccine adjuvant. Target Receptor: Toll-like receptor 3 (TLR3) | interferon-induced helicase C domain-containing protein 1 (MDA5)| antiviral innate immune response receptor RIG-I (RIG-I). Induces Th1-biased immune profile. TLR3, possibly RIG-I - agonist; Induces mucosal immunity, Induces CD8 T cells, Provides innate protection |
| Related Vaccine(s) |
|
| References |
(Lopez, 2021): Vaccine Adjuvant Compendium (VAC) [https://vac.niaid.nih.gov/view?id=30]
Mercado-López et al., 2013: Mercado-López X, Cotter CR, Kim WK, Sun Y, Muñoz L, Tapia K, López CB. Highly immunostimulatory RNA derived from a Sendai virus defective viral genome. Vaccine. 2013; 31(48); 5713-5721. [PubMed: 24099876].
|
|
